Association of Sarcopenia With Global, Motor, Cognitive, and Swallowing Function Prognosis in Stroke Patients: A Systematic Review and Meta-Analysis.

Brain BehavOct 1, 2026
Clinical ResearchGeriatricsNeurologyPhysical Medicine & Rehabilitation

Dandan Xie, Mingming Ma, Lu Chen

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of sarcopenia on functional outcomes in stroke patients. Analyzing 36 cohort studies, it found that patients with sarcopenia had a significantly higher risk of poor global functional prognosis (mRS, OR = 2.43, 95% CI: 1.95 to 3.03, p < 0.001) compared to those without sarcopenia.

Key findings

  • Stroke patients with sarcopenia had an odds ratio of 2.43 for poor global functional prognosis (mRS).
  • Motor function scores were significantly lower in the sarcopenia group (FIM-motor, SMD = -0.94).
  • Cognitive function scores were also significantly lower in patients with sarcopenia (SMD = -0.95).
  • The risk of swallowing dysfunction was elevated but not statistically significant (OR = 1.45).

Why it matters

Understanding the association between sarcopenia and functional outcomes in stroke patients is crucial for clinicians. It highlights the need for routine screening and potential interventions to improve patient prognosis and quality of life.

Source

PubMed · PMID 42811735

Published in Brain Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.